Private equity activity in the pharmaceutical industry in China increased in 2023
In value terms, private equity deal activity in China remained flat in Q2 2023 compared with the previous quarter and as compared to Q2 2022. Related deal volume increased by 500% in Q2 2023 versus the previous quarter and was 500% higher than in Q2 2022.
For further understanding of GlobalData’s Pharma Industry Mergers and Acquisitions Deals by Top Themes, buy the report here.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Deals Database tracks global deal activity, including mergers, acquisitions, capital raising, strategic alliances, and licensing agreements. Proprietary analysis is used to group deals into key thematic areas and granular sectors across the world’s largest industries.
This analysis considers only announced and completed deals from the GlobalData financial deals database and excludes all terminated and rumoured deals. Deal type includes Buyouts and Direct Investments done by Private Equity firms.
Source link
#Private #equity #activity #pharmaceutical #industry #China #increased
